Huntsman Cancer Institute established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Howard Colman, MD, PhD is a physician-scientist specializing in the treatment of brain tumors and the diagnosis and management of neurologic complications of cancer.
Clinical Trials Posts
Huntsman Cancer Institute established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Adam Cohen, MD, MS, was recently honored with a Huntsman Translational Scholar award. He is a researcher and physician, specializing in neuro-oncology and breast oncology.
With the recent news of Senator John McCain’s glioblastoma diagnosis, we asked the experts at Huntsman Cancer Institute about symptoms, diagnosis, and treatment of this cancer.
Are you thinking about taking part in a clinical trial? Read these five frequently asked questions about clinical trials.
HCI established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Deborah Stephens, DO, was recently honored with a Huntsman Translational Scholar award. She is the physician leader of the Hematology Clinical Trials at Huntsman Cancer Institute and is also an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah.
HCI established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Theresa Werner, MD, was recently honored with a Huntsman Translational Scholar award. She is the medical director of Clinical Trials and treats patients with gynecologic cancers.
Huntsman Cancer Institute celebrates International Women's Day 2018 in a conversation with Dr. Theresa Werner. Her patients juggle treatment with lives that often include work, a relationship, and motherhood. She talks with us about the optimistic women she treats in clinic and a stylish first lady of the United States she would trade lives with for a day.
This infographic highlights a few of Huntsman Cancer Institute's accomplishments in 2017.
Targeted therapy in cancer treatment is often called personalized or precision medicine, according to the National Institutes of Health. Targeted therapies are designed to be more effective and less harmful than other approaches because the drugs are specially designed to meet the individual characteristics of each patient.
All cancer treatments and medications that are used today were, at one point, part of a clinical trial. Clinical trials can offer hope, particularly in complex diseases such as cancer. But getting access to them can be difficult, especially if patients have to travel a long distance to a hospital that offers trials
Our bodies fight cancer more than we really know, says Kenneth Grossmann, MD, PhD, a medical oncologist at Huntsman Cancer Institute (HCI) and assistant professor of dermatology at the University of Utah (U of U). And, he adds, advances in medicine can help the immune system fight cancer even better.
Congratulations to Theresa Werner, MD, Huntsman Cancer Institute (HCI) investigator and University of Utah assistant professor of medicine, who received a 2016 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). Dr. Werner serves as medical director of the HCI Clinical Trials Office and manages an extensive portfolio of cancer clinical studies.
Clinical trials for some cancer patients may be the last, best hope for survival. A phase I trial is the first time a treatment is studied in people—usually a select number of patients who have not had success with other treatments. A rigorous process of approval takes place before doctors test these new therapies on patients for the first time.
Inheriting a mutation in the APC gene leads to a nearly 100% lifetime risk of colorectal cancer. While colon cancer can be kept at bay by removing the large intestine, these patients also have up to a 15% risk of getting cancer in the small intestine, which is the leading cause of cancer death in this patient group. A new study published in the Journal of the American Medical Association (JAMA) has identified the first prevention treatment for these patients, a two-drug combination that significantly reduces the number and size of precancerous polyps in the small intestine.
Walking into clinic, I found the patient and his wife looking tired and apprehensive. From what I knew of his medical history, his cancer had not responded to any standard treatments, each drug failing to restrain the tumor’s advance for more than a few months. The patient and his wife had talked to their local cancer doctor about clinical trials, had traveled hundreds of miles to Huntsman Cancer Institute, and were clearly anxious to begin the discussion.